line-up give us paus downgrad neutral
messag downgrad neutral buy sinc see limit
sourc upsid consensu estim near term continu struggl
meaning grow rubraca sale approv indic outlook
improv near term competitor drug gain traction front-lin ovarian
cancer treatment run broad develop program aim
expand rubraca use type cancer trial complet
think prostat cancer repres potl growth driver pend
approv think alreadi reflect consensu estim lower
rubraca sale street consensu announc rubraca sale
includ us eu miss consensu
us rubraca sale grew qoq eu sale decreas
management attribut product in-stock initi eu launch march free drug
suppli increas slightli gross-net adjust remain around
guid rubraca sale vs street consensu
suggest expect qoq growth
limit upsid ovarian cancer near term view continu
market effort increas awar parp inhibitor mainten therapi also
aim gain market share two competitor lynparza azn zejula
gsk said growth still appear slow recurr mainten therapi
set see exhibit adopt parp inhibitor still appear
accord trend chang slowli new competit front-
line ovarian cancer could addit headwind athena trial read
potenti sever pivot competitor trial front-lin ovarian cancer mainten
alreadi report posit result includ azn brca patient
recent gsk prima trial all-com result azn lynparza
avastin all-com also guid per azn manag
sever potenti rubraca label extend trial on-going near-term news flow
beyond prostat cancer limit besid athena recruit sever
registration-direct trial pursu label extens opportun includ confirmatori
phase phase mcrpc phase pan-tumor studi patient
solid tumor hrr mutat among reiter guidanc file
snda rubraca brca recist respons evalu mcrpc year-end
alreadi reflect consensu estim said prostat cancer could
potenti becom equal competit ovarian cancer result azn profound
trial guid galahd trial talapro trial continu enrol
updat estim street consensu lower rubraca net sale
estim vs street
consensu estim driven follow
underli assumpt ovarian cancer model peak market
share rubraca ovarian cancer patient elig maintenance/
treatment therapi parp inhibitor lead rubraca ww peak sale
ovarian cancer prostat cancer assum market share rubraca
mcrpc patient base differ treatment set lead ww sale
page analyst certif import disclosur
guggenheim secur llc estim compani fill oc ovarian cancer bc breast cancer
page analyst certif import disclosur
valuat risk
downgrad neutral buy remov price target follow
announc financi result adjust forecast rubraca ovarian cancer
prostat cancer reflect view intens competit therapeut space also
remov potenti revenu breast cancer base statu on-going clinic trial
collabor
 regulatori commerci setback
potenti emerg new competitor
dilut financ beyond assum
pipelin success beyond alreadi account model
page analyst certif import disclosur
total cost expens
total incom expens
incom tax
guggenheim secur llc estim sec file
page analyst certif import disclosur
fx loss expens
total incom expens
incom tax
guggenheim secur llc estim sec file
page analyst certif import disclosur
